Institution Directory

Clinical trials at Columbia University Irving Medical Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1202

Shown on this page

Current sort

Live official records

Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions: Rosuvastatin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Platinum-resistant Ovarian Cancer
Interventions: Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 72
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 22
States / cities: Duarte, California • Orange, California • Palo Alto, California + 19 more

Conditions: Prostatic Neoplasms
Interventions: JNJ-78278343, JNJ-87189401, Apalutamide, Lutetium Lu-177 Vipivotide Tetraxetan, JNJ-101556143; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Aurora, Colorado • Atlanta, Georgia • Minneapolis, Minnesota + 9 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Tacabrutideg, Pirtobrutinib; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 42 more

Conditions: Cardiovascular Diseases, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Coronary Artery Disease
Interventions: CT(Computed Tomography) guided Percutaneous Coronary Intervention, IVUS (Intravascular Ultrasound) guided Percutaneous Coronary Intervention; Device
Lead sponsor: Fundación EPIC; Other
Eligibility: 18 Years to 85 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Jersey City, New Jersey + 1 more

Conditions: NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions: IDE892, IDE397; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more

Conditions: Colitis, Ulcerative
Interventions: Golimumab, Infliximab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 12
States / cities: San Francisco, California • Aurora, Colorado • Lone Tree, Colorado + 9 more

Conditions: Liver Transplant
Interventions: Immunosuppression Reduction; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 13 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
Interventions: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more

Conditions: Advanced or Metastatic Colorectal Cancer
Interventions: Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Amivantamab; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more

Conditions: Carcinoma, Non-small-Cell Lung
Interventions: JNJ-86974680, Cetrelimab, Radiation Therapy; Drug · Radiation
Lead sponsor: Johnson & Johnson Enterprise Innovation Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Newnan, Georgia • Hackensack, New Jersey • Buffalo, New York + 4 more

About this Columbia University Irving Medical Center institution page

What this page lists: ClinicalTrials.gov records that list Columbia University Irving Medical Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Columbia University Irving Medical Center

Filter and sort this campus

Live official records

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

About this Columbia University Irving Medical Center institution page